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Abstract
Introduction Cohort event monitoring (CEM) is an
intensive method of post-marketing surveillance for
medicines safety. The method is based on prescription
event monitoring, which began in the 1970s, and has since
been adapted by WHO for monitoring the safety of
medicines used in Public Health Programmes. CEM aims
to capture all adverse events that occur in a defined group
of patients after starting treatment with a specific medicine
during the course of routine clinical practice.
Objective The aims of this study were to describe the
experiences of National Pharmacovigilance Centres (NCs)
that have used CEM to monitor artemisinin-based combi-
nation therapy (ACT) for uncomplicated malaria in the
African setting, to raise awareness of some of the chal-
lenges encountered during implementation and to highlight
aspects of the method that require further consideration.
Method A questionnaire-based survey was conducted to
capture the experiences of NCs that have implemented
CEM for active post-marketing surveillance of antimalarial
medicines in sub-Saharan Africa. Six NCs were identified
as having implemented CEM programmes and were invited
to participate in the survey; five NCs indicated willingness
to participate and were sent the questionnaire to complete.
Results Four NCs responded to the survey—Ghana,
Kenya, Nigeria and Zimbabwe—providing information on
the implementation of a total of six CEM programmes.
Electronic supplementary material The online version of this
article (doi:10.1007/s40264-015-0331-7) contains supplementary
material, which is available to authorized users.
& Comfort Kunak Suku
kunacom@yahoo.com
1 National Pharmacovigilance Centre, National Agency for
Food and Drug Administration and Control (NAFDAC),
Abuja, FCT, Nigeria
2 Uppsala Monitoring Centre (UMC), Uppsala, Sweden
3 National Pharmacovigilance Centre, Food and Drug
Authority (FDA), Accra, Ghana
4 National Pharmacovigilance Centre, Pharmacy and Poison
Board (PPB), Nairobi, Kenya
5 Present Address: Bayer HealthCare, Middle Africa Region,
Nairobi, Kenya
6 National Pharmacovigilance Centre, Medicine Control
Authority of Zimbabwe (MCAZ), Harare, Zimbabwe
7 Department of Clinical Pharmacology, College of Health
Sciences, University of Zimbabwe, Harare, Zimbabwe
8 WHO Collaborating Centre (WHO CC) for Advocacy and
Training in Pharmacovigilance, School of Medicine and
Dentistry, University of Ghana, Accra, Ghana
9 Safety and Vigilance (SAV), WHO, Geneva, Switzerland
Key Points
Cohort event monitoring (CEM) provides an
opportunity to raise awareness of pharmacovigilance
among healthcare providers and encourage a
perception that pharmacovigilance falls within the
scope of clinical practice.
Detailed planning for every step in the
implementation of CEM is necessary to avoid costly
study prolongation.
CEM data collection and management should
integrate with existing patient management and
pharmacovigilance systems wherever possible, to
minimise workload.
Drug Saf (2015) 38:1115–1126
DOI 10.1007/s40264-015-0331-7
Their experiences indicate that CEM has helped to build
pharmacovigilance capacity within the participating NCs
and at the monitoring sites, and that healthcare providers
(HCPs) are generally willing to participate in implementing
the CEM method. All of the programmes took longer than
expected to complete: contributing factors included a
prolonged enrolment period and unexpectedly slow data
entry. All of the programmes exceeded their budget by
11.1–63.2 %. Data management was identified as a chal-
lenge for all participating NCs.
Conclusions The reported experiences of four NCs that
have undertaken CEM studies on ACTs indicate that
CEM has helped to build pharmacovigilance capacity
within NCs and monitoring sites and that HCPs are
willing to participate in CEM programmes; however, the
method was found to be labour intensive and data man-
agement was identified as a challenge. Reducing the
workload associated with CEM, particularly in relation to
data management, and integrating the method into the
routine work of HCPs and NCs should be considered for
future implementation.
1 Introduction
The introduction of artemisinin-containing anti-malarial
therapies in early 2000 for the treatment of uncomplicated
malaria in endemic countries highlighted a need for
studies that would yield more complete safety data in the
post-authorisation period, especially under large-scale use
where their safety had not been fully assessed. To meet
this need, a modified version of prescription event mon-
itoring [1–3] was proposed in 1998 [4] and was subse-
quently developed by the World Health Organization
(WHO) as cohort event monitoring (CEM), a method of
intensive post-marketing surveillance for medicines used
in public health programmes. Although initially developed
for monitoring artemisinin-based combination therapies
(ACTs), the method has since been adapted for use in
HIV/AIDS treatment programmes and is now being con-
sidered for use in tuberculosis control programmes [5–7].
CEM is intended for monitoring the safety of a new
chemical entity in the early post-marketing phase, but is
also suitable for monitoring older medicines with new
indications [5].
CEM is a prospective, observational (non-interven-
tional), cohort study that is undertaken early in the post-
marketing phase of a new drug. The method is designed to
capture all adverse events1 that occur in a defined group of
patients (the cohort) who are exposed to a specific, newly
marketed medicine during the course of routine clinical
practice [5]. CEM differs from its predecessor (prescription
event monitoring) in that the cohort is enrolled by the
healthcare provider instead of relying on prescription
details supplied by pharmacies (a practice not common in
resource-constrained settings).
Patients are enrolled in the cohort as they start treat-
ment on the monitored medicine (treatment initiation);
demographic information and medical information on the
patient’s disease status, pregnancy status, past medical
history, medication use and presenting symptoms is cap-
tured at this initial encounter. Any new medical events
(change in clinical condition, new symptoms or diagnoses,
or significant changes in laboratory parameters) that have
occurred during a defined comparator period prior to
starting the monitored medicine are also recorded at
treatment initiation. Patients are then followed up after a
defined interval (treatment review) to record any new
adverse events that began after starting treatment with the
monitored medicine, regardless of whether or not the drug
was suspected to have caused the event. The information
is sent to the National Pharmacovigilance Centre (NC),
where each reported event is assessed for causality to
determine the likelihood that the event was caused by the
monitored medicine, based on the WHO Uppsala Moni-
toring Centre (WHO-UMC) causality assessment system
[8].
By capturing all clinical events, regardless of suspicion
of causality, CEM has the potential to identify previously
unrecognised and unsuspected adverse drug reactions
(ADRs). The cohort data provides a denominator for
calculation of incidence rates and, because background
health information is collected at treatment initiation, it
may also be possible to identify risk factors for some
ADRs.
The CEM method has been used to monitor the safety of
antimalarial medicines in Ghana, Kenya, Nigeria, Tanzania
and Zimbabwe [9]. Practical handbooks have been pub-
lished by the WHO on how to conduct CEM in public
health programmes for malaria, HIV/AIDS and tuberculo-
sis [5–7]. Several CEM programmes have published their
results from monitoring selected ACTs [10–13], and one
1 An adverse event is described as ‘‘Any untoward medical occur-
rence temporally associated (i.e. associated in time) with use of a
medicinal product, but not necessarily causally related’’ (WHO).
Footnote 1 continued
Adverse events may include: (1) any new condition or diagnosis
recorded in patient’s medical record (favourable or unfavourable); (2)
reason for referral to a specialist or admission to hospital; (3) unex-
pected deterioration or improvement in concurrent/pre-existing con-
dition; (4) suspected drug reaction; (5) clinically important alteration
in laboratory values; (6) lack of expected therapeutic effect; (7)
pregnancy-related conditions; (8) events in infants exposed in utero;
(9) accidents; (10) death—including cause of death, if known.
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CEM programme has recently published preliminary
results from monitoring antiretrovirals [14]. Related pub-
lications identify challenges for implementing pharma-
covigilance in resource-constrained settings [15] and
propose strategies to complement spontaneous reporting
for monitoring the safety of medicines in public health
programmes [7]. This is the first paper to document country
experiences of CEM implementation. In this paper, we
report on the experiences of four NCs that have each
implemented one or more CEM programmes for ACTs in
the African setting, following the method outlined in the
WHO publication ‘A Practical Handbook on the Pharma-
covigilance of Antimalarial Medicines’ (the CEM hand-
book) [5]; we aim to raise awareness of some of the
challenges encountered during the planning and imple-
mentation process and to highlight aspects of the method
that require further development. The results of individual
CEM programmes are beyond the scope of this paper.
2 Methods
A questionnaire-based survey was conducted to capture the
experiences of African countries that have implemented the
CEM method for active post-marketing surveillance of
antimalarial medicines. The NCs of six African countries
that had implemented a CEM programme were contacted
to indicate their interest in sharing their experiences; five
NCs agreed to participate. A questionnaire was developed
in English and sent to the five NCs for feedback on the
content and wording of the questions to ensure there was
no ambiguity and that they could provide the required
information. A final version of the questionnaire (see
electronic supplementary material) was then sent out for
completion by the NCs. In the event that a country had
implemented more than one CEM programme, the NC was
requested to fill in a separate questionnaire for each CEM
programme. The questionnaire was circulated in October
2013 and responses were received between January and
May 2014.
The questionnaire was divided into three sections. The
first section concerned characteristics of the country,
including information about the structure of the health sys-
tem and pharmacovigilance in the country. The second
section focused on the preparation phase, including the
rationale for undertaking a CEM study, ethical approval,
stakeholders and funding, development of programme tools,
site selection, training and sensitisation. The third section
focused on the actual implementation of the CEM study,
including human resources, patient enrolment and follow-
up, data management and monitoring and evaluation. Two
final questions asked the respondents to consider the chal-
lenges and lessons learnt from undertaking the CEM study.
The responses from the completed questionnaires were
entered into an Excel spreadsheet that was organised into
the same sections as the questionnaire. Reponses from each
country were compared and themes identified. These
themes formed the basis for presentation of the results and
subsequent discussions.
3 Results
Survey responses were received from the NCs of four
countries—Ghana, Kenya, Nigeria and Zimbabwe; a fifth
country had agreed to participate but did not send a com-
pleted questionnaire.
3.1 Profile of Participating Countries
Population data for each of the countries that responded
and information on each of the NCs are presented in
Table 1. All of the four participating NCs are located
within the national medicines regulatory authority, as
shown in Table 1, which also shows the year that each of
the countries joined the WHO Programme for International
Drug Monitoring and indicates the size and activity of each
of the participating NCs.
3.2 Cohort Event Monitoring (CEM)
Programme(s) and Stakeholders
The four NCs undertook a total of six CEM programmes.
All six programmes monitored ACTs, particularly arte-
mether-lumefantrine (AL) and artesunate-amodiaquine
(AA). Table 2 provides an overview of each of the CEM
programmes.
The NCs in all four countries coordinated implementa-
tion of CEM in collaboration with other stakeholders such
as the national malaria control programme, selected
healthcare institutions/sentinel monitoring sites across the
country, national and international non-governmental
organisations (NGOs), the WHO and marketing authori-
sation holders.
3.3 Development and Pre-Testing of CEM Data
Collection Tools
The data collection forms used in the CEM programmes
were based on a template provided in the CEM handbook
[5]. Each programme adapted the template to suit their
specific needs. Four of the six CEM programmes pre-tested
the data collection tools by enrolling a small number of
patients at each monitoring site using the forms. Nigeria
did not pre-test the tools used during the pilot programme;
however, because the forms used during the pilot
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programme were used during the scale-up (with slight
modifications), the pilot served as a pre-test for the scale-
up programme.
3.4 Training
All participating NCs trained the CEM site teams on the
principles of pharmacovigilance and the CEM method
prior to commencement of the programme. The training
was either conducted centrally, where master trainers were
trained and equipped to train other members of the CEM
team, or through training meetings and/or on-site training
for site personnel. High staff turnover at some monitoring
sites and NCs necessitated frequent training for new
members.
3.5 Cohort Size and Monitoring Sites
Details of the number of patients enrolled into the cohort in
each CEM programme, the number, type and urban/rural
distribution of monitoring sites and the human resources
requirements are provided in Table 2. The criteria for site
selection included regional representation, interest and
willingness of the institutional contact person to participate
in pharmacovigilance and CEM, active participation of the
site in pharmacovigilance (measured by the number and
quality of ADR reports sent to the NC), malaria burden in
the locality and accessibility of the site. In addition to the
public sector health facilities, two programmes engaged
private sector community pharmacies for patient
monitoring.
3.6 Use of Incentives
All programmes reported using incentives to encourage
healthcare providers (HCPs) to participate in the
programme. The reasons given for using incentives were to
motivate the HCPs to collect quality data, to compensate
for their time, for logistics and transport support and to
ensure their commitment to the programme. The nature and
quantity of incentives was determined independently by
each country based on their operating environment and
local context. Details of the incentives provided to HCPs
are shown in Table 3.
Most respondents considered that it would not be pos-
sible to undertake CEM without providing incentives for
HCPs. The reasons stated were that CEM is demanding and
time consuming and since many HCPs were already
overworked, it is unlikely that they would take on addi-
tional work (especially work they consider to be outside
their primary responsibility) without an incentive. Only one
NC considered that it would be possible to undertake CEM
without incentives because of the ‘‘availability of profes-
sionals who would be willing to participate’’ but warned
that the ‘‘response rate might be low’’.
Five of the CEM programmes also provided incentives
for patients. The nature and quantity of the patient
incentives are detailed in Table 3. Opinions on the feasi-
bility of conducting CEM without incentives for patients
were equally split between the six programmes. In Zim-
babwe, where no incentive was given to patients, it was
reported that patients saw the monitoring as part of their
treatment and were appreciative of the treatment, espe-
cially at a time when the country was going through a
financially challenging period. The NC in Ghana offered
reimbursement of transportation costs by way of incentive,
but reported that ‘‘over 98 % of follow-up was by tele-
phone call’’ and ‘‘most patients did not take [the incentive]
even when they came back to report ADR’’. The NCs in
Kenya and Nigeria, on the other hand, both considered that
the programme would be unsuccessful without the use of
incentives for patients.
Table 1 Characteristics of countries participating in the survey on cohort event monitoring (CEM) programme implementation
Ghana Kenya Nigeria Zimbabwe
Population (million) 26 41 168 14
Urban population (%) 50 25 50 45
Agency responsible for pharmacovigilance Food and Drugs Authority Ghana PPB NAFDAC MCAZ
Year joined WHO Programmea 2001 2010 2004 1998
No. of pharmacovigilance staff at NC 6 8 26 10
No. of ICSRs committed to VigiBaseb in 2013 227 2324 4050 356
ICSRs Individual Case Safety Reports, MCAZ Medicines Control Authority of Zimbabwe, NAFDAC National Agency for Food and Drug
Administration and Control, PPB Pharmacy and Poisons Board, WHO World Health Organization
a The WHO Programme for International Drug Monitoring
b The Global ICSR Database of the WHO Programme for International Drug Monitoring
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3.7 Duration of Enrolment
Table 3 shows the target and actual time taken to enrol the
cohort. The time taken to complete enrolment exceeded the
targeted timeframe by 50–100 % in all but one of the
studies; only the Nigeria Pilot Programme was able to
complete enrolment within the projected timeframe.
3.8 CEM Data Management
All responding countries reported using paper-based data
collection forms. All completed CEM forms were sent to
the NC for centralised data entry into CemFlow [16]—an
electronic data management tool developed by UMC at the
request of WHO, specifically for CEM studies. Completed
forms were transmitted to the NC by a variety of means
including courier, hand delivery by site staff, pick up by
NC staff or leveraging of existing in-country distribution
channels such as those used by Ministry of Health or public
health programmes to distribute commodities within the
system. The time required for data entry ranged from
4 weeks to 2 years. The number of people involved in data
entry and the time taken to complete the task varied across
the studies. Some studies such as the Kenya CEM pro-
gramme for monitoring AL used dedicated data entry
clerks to enter the CEM data over a period of 4 weeks,
while other programmes such as the Nigeria Pilot CEM
study used temporary staff to enter data over a long period
of time. The Kenya NC reported that the CEM data man-
agement tool, CemFlow, ‘‘should be made more user-
friendly’’ and the Ghana NC commented that the ‘‘data
entry process has been one of the most challenging aspects
of the study’’, citing concerns over the use of pharma-
covigilance staff rather than data entry clerks for data
entry, incomplete development of CemFlow and a lack of
correlation between the data collection forms used in their
programmes and the CemFlow data entry interface.
3.9 Cost of CEM
The actual cost of the CEM programmes exceeded the
budgeted cost by 11.1–63.2 %. The funding sources for
each programme are shown in Table 2. Two of the pro-
grammes also obtained non-monetary contributions such as
insecticide-treated nets from stakeholders. The prolonged
enrolment period and unexpectedly slow data entry added
to the overall time and cost of the programme.
3.10 Effect of CEM on Spontaneous Reporting
The NCs of Nigeria and Zimbabwe reported a positive
effect of CEM on spontaneous reporting of ADRs while
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ADR reports received by their national spontaneous
reporting programme from sites participating in CEM.
3.11 Challenges and Lessons Learnt
The key challenges and lessons learnt identified by each of
the NCs in the course of implementing CEM are sum-
marised in Table 4.
4 Discussion
We report on the experiences of four African NCs that have
implemented the newly described CEM method for active
post-marketing surveillance of ACTs. Their experiences of
undertaking a total of six CEM programmes provide useful
information on the requirements and challenges of intro-
ducing safety monitoring of intensive medicines in
Table 4 Key challenges and
lessons learnt identified by each





Challenges: Sustaining enthusiasm of the study team; enrolling target number of
patients into cohort due to seasonal variation of malaria, strike action by HCPs,
delays in fund release and shortage of monitored medicines; delay in data entry
and analysis due to CemFlow issues including access and lack of analysis
capacity; use of pharmacovigilance staff rather than data entry clerks for data entry
Lessons: Pretesting helped to appreciate the need to get a convenient time for
follow-up call and obtain an alternate telephone number; increase patient
enrolment sites in line with target cohort; ensure that fields in data collection
tools are in line with fields in software to ensure seamless data analysis. NC and
CEM site staff gained skills in implementing CEM
Kenya Challenges: Inadequate funding; social, cultural and religious barriers (e.g. some
women could not give informed consent without permission from their husbands
and poor adherence to treatment during theMuslimRamadan period when patients
could only eat in the evening); strike action by HCPs; reduced malaria burden at
some sites; staff turnover; data entry and limited analytical functions in CemFlow
Lessons: A new treatment policy was implemented while CEM was ongoing that
made it mandatory to test for malaria before treatment, This helped to determine
a more realistic prevalence of malaria using CEM, which turned out to be less




Challenges: Insecurity in parts of the country; inadequate staff at some community
pharmacies leading to increased workload; high personnel turnover; initial lack
of cooperation by other staff at some sites; strike action by HCPs, more time
required to explain CEM and obtain informed consent from patients;
apprehension by some patients and unwilling to consent as they saw CEM as
something new; reluctance by some patients to provide their phone numbers;
preferential prescription of AL leading to early exhaustion of AL at some sites,
poor recollection of other medicines taken prior to use of ACT; low literacy
levels; faking of symptoms by patients to get incentives; lack of dedicated
personnel for data entry including use of temporary staff; poor internet access
Lessons: There is need to ensure timely supply of all study materials prior to
commencement, ensure periodic review of progress, pre-test data collection tools
and processes prior to commencement, sufficient funds are required and
dedicated data entry personnel are invaluable for data entry. Increased awareness
about pharmacovigilance in general
Zimbabwe Challenges: Erratic and delayed disbursement of funds subject to satisfactory
monthly acquittals before further disbursement, high staff turnover at all 84 sites
and NC, inadequate funding for data entry clerks, additional funds required to
pay data entry staff
Lessons: The 6-month pilot phase indicated that CEM was feasible and could be
scaled up. It also identified the need for quarterly re-training of healthcare
professionals and monthly supervisory visit to sites due to high staff turnover at
the monitoring sites. CEM was very good for monitoring safety of ACTs;
however, it is very expensive and requires adequate staff and follow-up tools
such as cell phones and internet which were not readily available in Zimbabwe at
the time. Pharmacovigilance advocacy and sensitisation. NC gained confidence
to conduct active pharmacovigilance
AMFm Affordable Medicines Facility for malaria, HCPs healthcare providers, NC National Pharma-
covigilance Centre, WHO World Health Organization
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resource-limited settings. It is important to document the
experiences of these early implementations to inform fur-
ther development and refinement of the method and to shed
light on some of the practical issues that need to be con-
sidered when planning such a programme in this setting.
The survey focused only on practical issues of implemen-
tation and did not cover issues relating to data analysis or
the study results.
Overall, each of the NCs reported similar experiences.
All of the CEM programmes took longer than expected to
complete. A number of unforeseen delays contributed to
the prolonged timeframe for implementation, including the
time required to obtain individual informed consent, strike
action by healthcare workers, seasonal variation in malaria
cases and lower than anticipated incidence of malaria in
some regions (which prolonged the patient enrolment
period in some programmes), shortage of monitored
medicines, insecurity in some regions, delays in disburse-
ment of funds, attrition of trained site personnel and
insufficient data entry staff leading to unexpectedly slow
data entry. One programme also reported that the time
taken to obtain ethical approval was longer than antici-
pated, contributing to a delay in starting the study.
Although it is not possible to plan for all contingencies,
awareness of potential pitfalls may help to avoid some of
the factors that contributed to the extended study duration
in these programmes.
4.1 Site Selection
To facilitate timely enrolment, the monitoring sites should
be selected to include regions with the highest prevalence
of the disease for which the monitored medicine is used.
Site selection should also take into consideration the rep-
resentativeness of the cohort, the willingness and capacity
of the HCPs to participate in the monitoring and the
accessibility of the sites. Selection of sites in these CEM
programmes was predominantly influenced by a need for
representative geographic distribution, although malaria
prevalence and willingness of HCPs to participate were
also seen as important factors. Less frequently reported
factors were the prior experience of ADR reporting,
accessibility of the sites and health sector representation.
Two of the CEM programmes (the Nigerian Scale-Up
and Zimbabwe studies) engaged private-sector health
facilities (community pharmacies) for monitoring the
ACTs. Up to 82 % of all malaria episodes in sub-Saharan
Africa are managed outside the official health sector and
the private sector accounts for 40–60 % of all antimalarial
drugs distributed, with unofficial sources such as street
sellers and market stalls accounting for as much as 25 %
[17, 18]. Including community pharmacies in the moni-
toring programme may help to increase the rate of
enrolment and enhance the representativeness of the
cohort. In the programmes where community pharmacies
were engaged, enrolment still took longer than expected,
but the NCs cited a number of other problems (Table 4)
that delayed their progress.
4.2 Timing of CEM Implementation
The timing of the monitoring should allow for seasonal
variation in the disease prevalence, and monitoring of
ACTs should be planned to coincide with the peak malaria
season. The CEM programme for ACTs in Kenya reported
that a number of unforeseen delays (e.g. strike action by
nurses, doctors and pharmacists and the Muslim Ramadan
period in some areas) extended the planned monitoring
period beyond the malaria season, thereby prolonging the
overall time taken to complete the enrolment. Only three of
the six programmes met their enrolment target, and only
one (Nigeria Pilot study) achieved their target within the
anticipated time frame.
4.3 Informed Consent
The time required to inform patients about the purpose of
the monitoring and to obtain their informed consent was
identified as a factor in prolonging the study duration in
one of the studies. The CEM Handbook warns that
explaining the rationale and requirements of the monitoring
programme to individual patients will be time consuming,
increase complexity and add to the cost—a concern that
proved true in practice. A further caveat in the handbook
stated that a requirement for formal informed consent could
potentially compromise the validity of the results if many
patients refused to be enrolled [5]. CEM is a non-inter-
ventional, observational study; all patients who are pre-
scribed the monitored medicine during the course of
routine clinical practice and who are willing to participate
are eligible for enrolment in the cohort. Consent may be
required to collect their personal health information and to
be contacted for a follow-up interview. For CEM pro-
grammes where obtaining informed consent is a require-
ment by the ethics committee, NCs need to carefully plan
how to obtain full informed consent, taking into consid-
eration the time required to explain the purpose of the study
to patients and how their data will be stored and used, so
that sufficient resources can be allocated.
Unforeseen challenges that were reported in relation to
obtaining informed consent included socio-cultural barriers
such as women requiring their husband’s permission to
give consent, apprehension about signing the form, con-
cerns about HCPs calling to enquire about treatment pro-
gress and communication barriers created by low literacy
levels.
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4.4 Data Management
The UMC, in collaboration with WHO, developed a data
management tool, CemFlow, specifically for CEM studies.
The tool was still under development at the time these
CEM studies were implemented and was not fully opti-
mised for data management. Direct data entry at the point
of care was technically possible with CemFlow, but limited
IT capacity at the monitoring sites made it impracticable;
hence, all of the CEM programmes used paper-based data
collection forms with subsequent centralised manual data
entry into CemFlow.
All of the NCs reported experiencing challenges with
data management. The CEM method requires data capture
at each patient encounter. For ACTs, which generally
involve a 3-day course of treatment, CEM requires a data
collection form to be completed at the time of treatment
initiation and at treatment review after a specified period of
time, thereby generating at least two forms per patient.
Consequently, the amount of data to be manually entered
into the data management tool is very large. For example,
the Nigeria Scale-Up programme, in which 10,260 patients
were successfully followed-up after treatment initiation,
necessitated manual data entry into CemFlow from at least
20,520 paper forms. All of the NCs reported that they had
insufficient dedicated data entry clerks, and additional data
entry clerks, including NC pharmacovigilance staff, were
enlisted to complete the task.
It is worth noting that CEM of ACTs, with just two
forms per patient, requires considerably less work than
would be generated by a CEM study for a longer term
therapy such as an antiretroviral medicine, in which
patients would need to be followed up multiple times
over a longer period (e.g. monthly for a year). NCs
planning to implement CEM, especially when centralised
manual data entry is unavoidable, must consider how to
effectively manage the data that will be generated,
including having an adequate number of staff for data
entry.
The long-term solution may be the increased use of
electronic health records (EHRs) that enable signal detec-
tion in longitudinal health data [19]. In the shorter term,
EHRs and other digital technologies such as mobile phone
applications that facilitate electronic data capture may be
developed to reduce the workload associated with CEM.
Access to computers, stable Internet connections and a
constant electricity supply remain a challenge in many
African countries [20, 21], but mobile phone technology is
now widespread. Mobile phone ADR reporting apps have
already been developed and are in use, for example in
Kenya [22], and could be considered as a possible reporting
tool for CEM studies.
4.5 Healthcare Providers’ Participation
All NCs reported an initial high level of enthusiasm by
HCPs, which waned with time to a level of almost reluc-
tance to continue. The initial enthusiasm shows that HCPs
in resource-limited settings are willing to participate in
pharmacovigilance activities. The reasons behind the
waning interest were not solicited in the questionnaire.
There appears to be a perception among HCPs, espe-
cially in developing countries, that CEM, and by extension
pharmacovigilance, falls outside their scope of practice.
This perception is reflected in the response to the question
‘‘How would the (monitoring) sites best describe the
additional workload associated with CEM’’. All of the NCs
responded that the monitoring sites considered that CEM
interfered to a great extent with their routine work. These
responses suggest that the HCPs involved in these CEM
programmes had not fully appreciated the rationale for
undertaking the CEM study and that pharmacovigilance
activities should be considered an integral component of
patient care. Although the number of developing countries
that have joined the WHO Programme for International
Drug Monitoring has increased sharply in recent years [23,
24], pharmacovigilance in many of these countries is not
yet seen by HCPs as contributing to clinical decisions and
improving treatment outcomes. There is a need for greater
pharmacovigilance advocacy and training for HCPs to
encourage their ongoing participation in future CEM
studies.
The effect of diminishing returns may also have played
a role in the loss of enthusiasm reported by each of the
NCs. Many of the HCPs may have lost interest when the
programme that was intended to be a short-term project
extended beyond the expected timeframe. NCs that are
planning to implement CEM need to carefully estimate the
time commitment that will be required of participating
HCPs, and endeavour to integrate data collection into their
routine patient care activities.
Despite the waning of enthusiasm, the NCs reported
positive experiences in relation to the participation of
HCPs, including improved patient–HCP interaction,
greater understanding of pharmacovigilance and more
rational use of ACTs.
4.6 Cost of CEM
In all of the programmes, the actual expenditure on CEM
exceeded the budget by 11.1–63.2 %. Factors that con-
tributed to budget shortfalls included the unexpectedly
prolonged study duration and the need to hire additional
data entry clerks. A breakdown of the budget was not
included in the survey questionnaire.
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The use of incentives for HCPs (and, in most cases,
patients) added to the cost of the CEM programmes.
Although most NCs considered that implementing CEM
would be difficult without the use of incentives, this is a
potential target for cost reduction. Another target for cost
reduction is the workload associated with patient enrolment
and data entry. Electronic data capture inCEMstudieswould
reduce the time and labour required for data processing.
4.7 Effect of CEM on Spontaneous Reporting
Two NCs reported a positive effect on spontaneous
reporting of ADRs while two reported a reduction in the
number of ADR reports from sites participating in CEM.
The probable explanation for the observed reduction is that
the same people who would have reported ADRs at the
sites were engaged in CEM, thus leaving them with little
time to routinely report ADRs. However, the survey
responses indicate that the experience of implementing
CEM helped to build pharmacovigilance capacity within
the NCs and the monitoring sites, which can be expected to
have a positive effect on routine pharmacovigilance
activities in the long run [25].
4.8 Limitations of the Survey
The questionnaire was validated by the same people who
completed the survey, but foreknowledge of the question-
naire content was thought unlikely to compromise the
survey results in any way. Some of the questions were
directed to the HCPs at the monitoring sites; however, it is
not clear whether the NCs solicited responses for these
questions from the sites or responded on their behalf. Thus,
the responses may not be an accurate reflection of how
CEM was perceived by the monitoring site personnel. The
questionnaire was also limited in the depth of information
required from respondents. It did not enable a probe into
the reasons for issues such as the delay in obtaining ethical
approval experienced by one of the NCs, information on
individual cost items and their relative contribution to the
total cost of CEM, and the waning interest of HCPs par-
ticipating in the programme.
5 Conclusion
This survey documents the experiences of four African
NCs that have implemented the CEM method for moni-
toring ACTs. Their experiences indicate that CEM has
helped to build pharmacovigilance capacity within the NCs
and monitoring sites, and HCPs are generally willing to be
involved in implementing the CEM method. Pharma-
covigilance advocacy and education towards integrating
patient monitoring into the routine patient care activities of
HCPs will improve appreciation of CEM as a compli-
mentary tool for drug safety monitoring. Reducing the
workload associated with CEM, for both the HCPs and NC
staff, particularly in the area of data management, should
be considered a priority for further development of the
method.
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